Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 7, 2016

Micro Interventional Devices’ Permaseal secures CE mark approval

US-based medical technology company Micro Interventional Devices (MID) has secured the CE mark approval for its transapical access and closure device, Permaseal.

Permaseal

US-based medical technology company Micro Interventional Devices (MID) has secured the CE mark approval for its transapical access and closure device, Permaseal.

Permaseal is a high-speed delivery system that operates on compliant soft-tissue PolyCor anchor technology, which places an implant on the myocardium via a mini-thoracotomy.

The implant is made from eight PolyCor anchors and one coated, non-absorbable, green braided polyester surgical suture enabling surgeons closer access to the left-ventricle without having to suture the myocardium.

Following the delivery of the implant, Permaseal closes the access site. The access and closure process is quick, reduces blood loss and simplifies the complex structural heart repair processes.

"Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures."

Permaseal facilitates a minimally-invasive procedure which can be repeated multiple times, independent of the operator.

MID founder president and CEO Michael Whitman said: "Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

"We are excited that this technology is now available to our European surgeons and their patients."

The secure transapical access and closure study (STASIS) conducted at five European Sites has validated Permaseal after it was observed that it led to reduced opening time, duration of hospital stay, need of transfusion and 12-month mortality, as well as reducing stroke rates to 0%.


Image: A view of MID’s Permaseal. Photo: PRNewsFoto / Micro Interventional Devices.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU